


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-14.44%
+22.49%
+0.48%
+12.65%
+2.37%
ABT
Abbott Laboratories
$125.08
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Investors confidence is positive
ABT Price Performance
$125.89 (-0.64%)
$133.73 (-6.47%)
$120.51 (+3.79%)
$112.42 (+11.26%)
ABT has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

ABT overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Eps growth

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
ABT Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
ABT Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayCVKD
10.18
-8.29%
MRK
99.72
-1.16%
PFE
26.03
+1.28%
OGN
7.14
0.00%
MTNB
0.79
+5.19%
What is ABT current stock price?
What are ABT stock strengths?
What is ABT Risk Level?
What is ABT market cap and volume?
What is ABT current Stock IQ?
Should I buy ABT stock right now?
Is ABT a Strong Buy right now?
What does a 'Strong Buy' rating mean for ABT?
What does a 'Strong Sell' rating mean for ABT?
What factors influence ABT's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-14.44%
+22.49%
+0.48%
+12.65%
+2.37%
ABT
Abbott Laboratories
Current Price
$125.08
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Investors confidence is positive
Linked to ABT
CVKD
10.18
-8.29%
MRK
99.72
-1.16%
PFE
26.03
+1.28%
OGN
7.14
0.00%
MTNB
0.79
+5.19%

ABT Price Performance
$125.89 (-0.64%)
$133.73 (-6.47%)
$120.51 (+3.79%)
$112.42 (+11.26%)
ABT Analysts Opinion
ABT Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Eps growth

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
ABT Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
ABT Street Sentiment is bullish and have positive views on the near-term outlook
ABT has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
ABT Stock IQ
ABT Latest Analysis
Peter Lynch Detailed Fundamental Analysis - ABT. Below is Valideas guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relat
Fri Dec 5, 2025
FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries 7 Deaths. The United States Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by ABT) Diabetes Care after the company linked the devices to seven deaths and hundreds of serious injuries.Regulators said certain models of the company'.s potentially prompting dangerous treatment decisions.In a published earlier in December
Fri Dec 5, 2025
Top Analyst Reports for HSBC Abbott & Shell. HSBCs Asia pivot Abbotts device momentum and Shells resilient Q3 results headline todays standout analyst reports.
Thu Dec 4, 2025
Muscles the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement. Aging nutrition and lifestyle affect muscles especially after age 40. Thats why Matt Ryan former professional quarterback and MVP is teaming up with Abbott to drive muscle health awareness with two new Ensure Max Protein shakes Ensure Max Protein 42g: For physically active adults...
Thu Dec 4, 2025
ABT Factor-Based Stock Analysis - Peter Lynch. Below is Valideas guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relat
Wed Dec 3, 2025
Peter Lynch Detailed Fundamental Analysis - ABT. Below is Valideas guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relat
Mon Dec 1, 2025
Peter Lynch Detailed Fundamental Analysis - ABT. Below is Valideas guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relat
Fri Nov 28, 2025
ABT Factor-Based Stock Analysis - Peter Lynch. Below is Valideas guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relat
Wed Nov 26, 2025
Eric Shroff Executes Sell Order: Offloads $203K In Abbott Laboratories Stock. Disclosed on November 25 ABT) executed a substantial insider sell as per the latest SEC filing.United States Securities and Exchange Commission on Tuesday. The total value of the sale is $203042.The latest update on Wednesday morning shows Abbott manufactures and markets cardiovascular and diabetes devices adult and pediatric nutritional products diagnostic equipment and testing kits and branded generic drugs. Products
Wed Nov 26, 2025
Abbott Launches Medical Device Correction For FreeStyle Libre 3 Glucose Sensors In United States . (RTTNews) - Abbott Laboratories (ABT) has initiated a medical device correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring systems after internal testing found that some sensors may deliver incorrect low glucose rea
Tue Nov 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.